Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomas G Neilan

Showing results (11-20 of 259) with videos related to

Pageof 26
Sort By:
European Heart Journal|October 4, 2016
Cardiovascular side effects of small molecule therapies for cancerShawn C Pun, Tomas G Neilan
JACC. Heart Failure|March 5, 2020
Reply: Death, Heart Failure, and HIV: Have We Got it the Wrong Way Around?Raza M Alvi, Tomas G Neilan
European Heart Journal|December 8, 2020
Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?Matthias Totzeck, Esther Lutgens, Tomas G Neilan
European Heart Journal|August 30, 2022
Cardiovascular complications of immune checkpoint inhibitors for cancerFranck Thuny, Jarushka Naidoo, Tomas G Neilan
Cardiology Clinics|October 8, 2019
Cardiotoxicity of Immune TherapySarju Ganatra, Rohan Parikh, Tomas G Neilan
Journal of the American College of Cardiology|December 3, 2014
Obstructive sleep apnea and atrial fibrillation: is the link real?Atul Malhotra, Tomas G Neilan, Kathleen Sarmiento
Journal of the American College of Cardiology|July 23, 2021
Reply: Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving TargetPaaladinesh Thavendiranathan, Lili Zhang, Tomas G Neilan
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 15, 2021
Call on the reserve: Coronary vasomotor dysfunction is a potential biomarker of cardiovascular risk in patients with breast cancerMichael T Osborne, Simran Grewal, Tomas G Neilan
Current HIV/AIDS Reports|September 5, 2019
Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive ConsiderationsMabel Toribio, Tomas G Neilan, Markella V Zanni
Blood|February 24, 2023
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapyCristina Gutierrez, Tomas G Neilan, Natalie S Grover
Pageof 26

Showing results (11-20 of 259) with videos related to

Sort By:
Pageof 26
European Heart Journal|October 4, 2016
Cardiovascular side effects of small molecule therapies for cancerShawn C Pun, Tomas G Neilan
JACC. Heart Failure|March 5, 2020
Reply: Death, Heart Failure, and HIV: Have We Got it the Wrong Way Around?Raza M Alvi, Tomas G Neilan
European Heart Journal|December 8, 2020
Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?Matthias Totzeck, Esther Lutgens, Tomas G Neilan
European Heart Journal|August 30, 2022
Cardiovascular complications of immune checkpoint inhibitors for cancerFranck Thuny, Jarushka Naidoo, Tomas G Neilan
Cardiology Clinics|October 8, 2019
Cardiotoxicity of Immune TherapySarju Ganatra, Rohan Parikh, Tomas G Neilan
Journal of the American College of Cardiology|December 3, 2014
Obstructive sleep apnea and atrial fibrillation: is the link real?Atul Malhotra, Tomas G Neilan, Kathleen Sarmiento
Journal of the American College of Cardiology|July 23, 2021
Reply: Imaging Edema in Immune Checkpoint Inhibitor Myocarditis: A Moving TargetPaaladinesh Thavendiranathan, Lili Zhang, Tomas G Neilan
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 15, 2021
Call on the reserve: Coronary vasomotor dysfunction is a potential biomarker of cardiovascular risk in patients with breast cancerMichael T Osborne, Simran Grewal, Tomas G Neilan
Current HIV/AIDS Reports|September 5, 2019
Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive ConsiderationsMabel Toribio, Tomas G Neilan, Markella V Zanni
Blood|February 24, 2023
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapyCristina Gutierrez, Tomas G Neilan, Natalie S Grover
Pageof 26